Loading...
OTCMCLLKF
Market cap203mUSD
Dec 26, Last price  
2.93USD
IPO
-71.75%
Name

BICO Group AB

Chart & Performance

D1W1MN
OTCM:CLLKF chart
P/E
—
P/S
1.00
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
19.96%
Rev. gr., 5y
179.25%
Revenues
2.24b
+78.12%
013,188,00045,337,000105,457,000176,793,0001,257,300,0002,239,500,000
Net income
-836m
L+264.62%
0155,0001,183,000581,000-61,888,000-229,200,000-835,700,000
CFO
-269m
L-34.16%
-179,000-12,263,000-15,818,000-71,817,000-409,200,000-269,400,000
Earnings
Feb 19, 2025

Profile

BICO Group AB (publ) operates as a bio convergence company in North America, Europe, Asia, and internationally. It operates through two segments, Laboratory Solutions and Bioautomation. The Laboratory Solutions segment offers 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments, as well as services and related consumables, such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues for applications in regulatory testing. This segment also offers services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharmaceutical and biotechnology companies. The Bioautomation segment offers products in precision dispensing and biosensor technology to the industrial customer; and diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. In addition, it offers core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions. It primarily serves medical, pharmaceutical, and cosmetic industries. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was founded in 2016 and is based in Gothenburg, Sweden.
URL
https://bico.com/
IPO date
Nov 03, 2016
Employees
1,069
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑082019‑082018‑082017‑082016‑08
Income
Revenues
2,239,500
78.12%
1,257,300
611.17%
Cost of revenue
1,127,900
688,100
Unusual Expense (Income)
NOPBT
1,111,600
569,200
NOPBT Margin
49.64%
45.27%
Operating Taxes
82,600
15,800
Tax Rate
7.43%
2.78%
NOPAT
1,029,000
553,400
Net income
(835,700)
264.62%
(229,200)
270.35%
Dividends
Dividend yield
Proceeds from repurchase of equity
540,600
5,109,500
BB yield
-7.64%
-29.98%
Debt
Debt current
97,700
58,300
Long-term debt
2,215,600
1,799,900
Deferred revenue
19,500
Other long-term liabilities
224,600
393,300
Net debt
1,388,100
1,373,600
Cash flow
Cash from operating activities
(269,400)
(409,200)
CAPEX
(529,600)
(267,000)
Cash from investing activities
212,900
(4,453,800)
Cash from financing activities
455,300
4,900,100
FCF
(84,800)
246,615
Balance
Cash
925,200
1,475,000
Long term investments
(990,400)
Excess cash
813,225
421,735
Stockholders' equity
(1,077,600)
(243,400)
Invested Capital
10,037,700
9,056,100
ROIC
10.78%
10.35%
ROCE
11.95%
6.27%
EV
Common stock shares outstanding
66,877
61,353
Price
105.80
-61.92%
277.80
68.36%
Market cap
7,075,570
-58.49%
17,043,853
144.54%
EV
8,490,870
18,446,253
EBITDA
2,052,200
761,000
EV/EBITDA
4.14
24.24
Interest
98,200
59,300
Interest/NOPBT
8.83%
10.42%